

# Highlights 2017/4-2018/3

## Calendar of Events FY2017

R&D Topics

### Development **Anticancer Drug OPDIVO Approved for Additional Indications around the World**

Additional Indications

- **Japan: September** | Gastric cancer
- **South Korea: August** | Renal cell carcinoma, Classical Hodgkin's lymphoma, Head and neck cancer, Urothelial carcinoma, Melanoma (first-line therapy/combination with Yervoy Injection); **March** | Gastric or esophago-gastric junction cancer
- **US: August** | MSI-H or dMMR metastatic colorectal cancer; **September** | Hepatocellular carcinoma; **December** | Adjuvant therapy in resected melanoma

### Alliance **Alliance Agreements Formed through Vigorous Licensing Activities regarding New Drug Candidates**

In-Licensing

- **Array Biopharma: May** | MEK inhibitor Binimetinib, BRAF inhibitor Encorafenib (rights to develop and commercialize in Japan and South Korea)
- **Seikagaku Corporation: August** | Osteoarthritis drug SI-613 (rights to co-develop and market in Japan)
- **Karyopharm Therapeutics: October** | Oral XPO1 inhibitor Selinexor, second-generation oral XPO1 inhibitor KPT-8602 (rights to develop and commercialize in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries)

2017/4

2017/5

2017/6

2017/7

2017/8

2017/9

Social Activity Topics

April to June

#### Great East Japan Earthquake reconstruction assistance activity "Operation Slimmer and Healthier in Iwate" conducted

Activities aimed at conveying the joy of sports and exercises to children of the disaster affected areas



May

#### Tree planting in Fuji-sanroku Nature Park undertaken

Participation in an activity that contributes to the local community



September

#### Hands-on learning program "Wonderful Water Expedition" for elementary school children co-sponsored

Co-sponsorship of hands-on learning in environmental education, encouraging students' interest in the water environment in the Mt. Fuji area

- **Europe: April** | Head and neck cancer; **June** | Urothelial carcinoma
- **Taiwan: April** | Renal cell carcinoma; **August** | Head and neck cancer; **September** | Non-squamous non-small cell lung cancer; **October** | Classical Hodgkin's lymphoma, Urothelial carcinoma, Melanoma (first-line therapy/combination with Yervoy Injection); **January** | Gastric or esophago-gastric junction cancer; **March** | Hepatocellular carcinoma

Out-Licensing

- **Bristol-Myers Squibb: December**  
Prostaglandin E2 Receptor Antagonist ONO-4578 (rights to develop and commercialize worldwide except in Japan, South Korea, Taiwan, China and ASEAN countries)

Development Collaboration

- **Eisai: September**  
Combination therapy of OPDIVO and multi-kinase inhibitor Lenvima for the treatment of hepatocellular carcinoma (joint development in Japan)

Open Innovation Research Alliance Agreements Formed to Adopt World-Leading Technologies and Knowledge

Drug Discovery Alliances

- **Neurimmune: November** | Drug discovery in neurodegenerative disease area exploiting antibody development technology
- **Cyclenium Pharma: December** | Drug discovery exploiting next generation synthetic molecule macrocyclic technology
- **Schrödinger: December** | Drug discovery using advanced computational methods
- **Merus: March** | Drug discovery in autoimmune disease area exploiting bispecific antibody development technology

2017/10

2017/11

2017/12

2018/1

2018/2

2018/3

November

**Outreach class program "Secrets of Pharmaceuticals!" conducted**

Continued conduct of outreach classes for students of the elementary school near the Minase Research Institute



December

**Participation in UN Global Compact**

Announcement of participation in efforts to establish a global framework for achieving sustainable growth



Network Japan  
WE SUPPORT

March

**Awardees announced for the 2018 Osamu Hayaishi Memorial Scholarship for Study Abroad**

Support to the Japanese Biochemical Society project established to enable many young researchers to study abroad

**Great East Japan Earthquake reconstruction assistance activity "Operation Slimmer and Healthier in Fukushima" conducted**

January to February

**Outreach classes conducted for middle and high school students**

Continued conduct of outreach classes on the theme of dementia